HomeWOCKPHARMA › Filing
🔔 Get instant alerts when WOCKPHARMA files quarterly results on BSE Start free trial →
Wockhardt Limited (WOCKPHARMA)

Please find enclosed Press Release - "Wockhardt Antibiotic Academy, an initiative for Patient-Centric Scientific Dialogue to Tackle Multidrug Resistance".

Filed: 10 Aug 2026, 18:05 IST Exchange: BSE Category: General Update — Press Release
Wockhardt launched the Antibiotic Academy to foster scientific dialogue on antimicrobial resistance. The platform aims to educate clinicians across India on evidence-based antibiotic use to combat multidrug resistance. The initiative encourages knowledge exchange and collaboration among healthcare professionals to improve patient outcomes. Wockhardt emphasizes its commitment to antibiotic discovery and stewardship. The Academy invites participation from clinicians, societies, hospitals, and policymakers to strengthen the fight against antimicrobial resistance.
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 WOCKPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add WOCKPHARMA to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Wockhardt Limited

Important. The summary above is generated automatically from Wockhardt Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.